Guillain-Barre Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon

The Guillain-Barre Syndrome Market Forecast report offers an in-depth understanding of the Guillain-Barre Syndrome, historical and forecasted epidemiology as well as the Guillain-Barre Syndrome market trends in the 7MM.
DelveInsight's "Guillain-Barre Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Guillain-Barre Syndrome, historical and forecasted epidemiology as well as the Guillain-Barre Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Guillain-Barre Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Guillain-Barre Syndrome Market Forecast [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Guillain-Barre Syndrome Market Report:

* The Guillain-Barre Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In December 2023, Hansa Biopharma, known as "Hansa," released encouraging preliminary findings from the phase 2 trial 15-HMedIdeS-09, showcasing the safety and tolerability of imlifidase alongside standard care. The trial demonstrated swift enhancements in disease-related effectiveness measures. Further evaluation of the efficacy data is scheduled for 2024. The 15-HMedIdeS-09 trial, designed as an open-label, single-arm study, evaluates the safety, tolerance, and efficacy of imlifidase in patients with Guillain-Barre Syndrome (GBS) in conjunction with standard intravenous immunoglobulin (IVIg) treatment.
* In October 2023, Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical firm specializing in novel complement-based therapies for autoimmune, neurodegenerative, and ophthalmic ailments, disclosed that the European Medicines Agency (EMA) has awarded orphan drug status to ANX005 for Guillain-Barre Syndrome (GBS) treatment. Previously, the U.S. Food and Drug Administration (FDA) had also granted ANX005 orphan drug status for GBS treatment.
* As per the National Organization of Rare Disorders (NORD) (n.d.), Guillain-Barre Syndrome (GBS) impacts approximately one to two individuals annually per 100,000 population. The precise cause of this condition remains uncertain. It's noted that around half of those affected experience a gastrointestinal or respiratory infection in the days leading up to the onset of symptoms.
* The outlook for Guillain-Barre Syndrome (GBS) varies depending on its specific form. While some patients achieve full recovery, others may still face challenges with walking six months after the onset of the disease. In severe cases, GBS can unfortunately lead to a fatal outcome.
* Key Guillain-Barre Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, and others
* Key Guillain-Barre Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
* The Guillain-Barre Syndrome epidemiology based on gender analyzed that Guillain-Barre Syndrome is more common in men than in women
* The Guillain-Barre Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Guillain-Barre Syndrome pipeline products will significantly revolutionize the Guillain-Barre Syndrome market dynamics.

Guillain-Barre Syndrome Overview

Guillain-Barre Syndrome (GBS) is a rare neurological disorder where the body's immune system mistakenly attacks its nerves. This condition leads to muscle weakness, numbness, and in some cases, paralysis. GBS often begins with tingling sensations and weakness in the legs, which can rapidly progress to affect the arms and upper body. In severe cases, GBS can cause paralysis of the entire body, including the muscles involved in breathing, requiring hospitalization and sometimes intensive care.

Get a Free sample for the Guillain-Barre Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market [https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Guillain-Barre Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Guillain-Barre Syndrome Epidemiology Segmentation:

The Guillain-Barre Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Guillain-Barre Syndrome
* Prevalent Cases of Guillain-Barre Syndrome by severity
* Gender-specific Prevalence of Guillain-Barre Syndrome
* Diagnosed Cases of Episodic and Chronic Guillain-Barre Syndrome

Download the report to understand which factors are driving Guillain-Barre Syndrome epidemiology trends @ Guillain-Barre Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Guillain-Barre Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barre Syndrome market or expected to get launched during the study period. The analysis covers Guillain-Barre Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Guillain-Barre Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Guillain-Barre Syndrome Therapies and Key Companies

* Efgartigimod Alfa-Fcab: Chafic Karam
* Imlifidase: Hansa Biopharma AB
* ANX005: Annexon, Inc.

Discover more about therapies set to grab major Guillain-Barre Syndrome market share @ Guillain-Barre Syndrome Treatment Landscape [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Guillain-Barre Syndrome Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Guillain-Barre Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, Inc., and others
* Key Guillain-Barre Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
* Guillain-Barre Syndrome Therapeutic Assessment: Guillain-Barre Syndrome current marketed and Guillain-Barre Syndrome emerging therapies
* Guillain-Barre Syndrome Market Dynamics: Guillain-Barre Syndrome market drivers and Guillain-Barre Syndrome market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Guillain-Barre Syndrome Unmet Needs, KOL's views, Analyst's views, Guillain-Barre Syndrome Market Access and Reimbursement

To know more about Guillain-Barre Syndrome companies working in the treatment market, visit @ Guillain-Barre Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Guillain-Barre Syndrome Market Report Introduction

2. Executive Summary for Guillain-Barre Syndrome

3. SWOT analysis of Guillain-Barre Syndrome

4. Guillain-Barre Syndrome Patient Share (%) Overview at a Glance

5. Guillain-Barre Syndrome Market Overview at a Glance

6. Guillain-Barre Syndrome Disease Background and Overview

7. Guillain-Barre Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Guillain-Barre Syndrome

9. Guillain-Barre Syndrome Current Treatment and Medical Practices

10. Guillain-Barre Syndrome Unmet Needs

11. Guillain-Barre Syndrome Emerging Therapies

12. Guillain-Barre Syndrome Market Outlook

13. Country-Wise Guillain-Barre Syndrome Market Analysis (2019-2032)

14. Guillain-Barre Syndrome Market Access and Reimbursement of Therapies

15. Guillain-Barre Syndrome Market Drivers

16. Guillain-Barre Syndrome Market Barriers

17. Guillain-Barre Syndrome Appendix

18. Guillain-Barre Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.